Why the study?
Antigen-specific therapy for multiple sclerosis may provide effective treatment through tolerance induction without impairing normal immune surveillance and effector function.
This review provides an overview of current approaches and future challenges for antigen-specific therapy in multiple sclerosis.
Antigen-specific MS tolerance approaches remain investigational; leaves open the need for rigorous human trials to define efficacy and durability.
Antigen-specific therapy for multiple sclerosis may lead to a more effective therapy by induction of tolerance to a wide range of myelin-derived antigens without hampering the normal surveillance and effector function of the immune system. Numerous attempts to restore tolerance toward myelin-derived antigens have been made over the past decades, both in animal models of multiple sclerosis and in clinical trials for multiple sclerosis patients. In this review, we will give an overview of the current approaches for antigen-specific therapy that are in clinical development for multiple sclerosis as well provide an insight into the challenges for future antigen-specific treatment strategies for multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Derdelinckx et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: